Header Logo

Connection

Debra Richardson to Humans

Back to Details
This is a "connection" page, showing publications Debra Richardson has written about Humans.
Debra Richardson
Connection Strength
0.991
Humans
  1. A trial of radiolabeled antibody yttrium-90-FF-21101 for the treatment of advanced ovarian and other cancers. Cancer. 2025 Jan 01; 131(1):e35680.
    View in: PubMed
    Score: 0.054
  2. The emerging use of antibody-drug conjugates in ovarian cancer. Clin Adv Hematol Oncol. 2023 05; 21(5):244-246.
    View in: PubMed
    Score: 0.048
  3. Is there a role for secondary debulking in ovarian cancer? A review of the current literature. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):1-5.
    View in: PubMed
    Score: 0.047
  4. OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol. 2022 08; 166(2):219-229.
    View in: PubMed
    Score: 0.045
  5. Should we or should we not? Secondary debulking in ovarian cancer. Lancet Oncol. 2021 04; 22(4):412-413.
    View in: PubMed
    Score: 0.042
  6. New and Novel Therapies for Gynecologic Cancers. Semin Oncol Nurs. 2019 Apr; 35(2):217-219.
    View in: PubMed
    Score: 0.036
  7. Antibody Drug Conjugates in the Treatment of Epithelial Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):1057-1071.
    View in: PubMed
    Score: 0.035
  8. Paclitaxel and Pazopanib in Ovarian Cancer-Reply. JAMA Oncol. 2018 09 01; 4(9):1299.
    View in: PubMed
    Score: 0.035
  9. Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. Am J Clin Oncol. 2018 08; 41(8):797-801.
    View in: PubMed
    Score: 0.035
  10. Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2018 Feb 01; 4(2):196-202.
    View in: PubMed
    Score: 0.034
  11. Risk of Occult Uterine Sarcoma in Women Undergoing Hysterectomy for Benign Indications. Obstet Gynecol. 2016 Mar; 127(3):468-473.
    View in: PubMed
    Score: 0.029
  12. Lymph node metastasis in endometrioid adenocarcinomas of the uterine corpus with occult cervical involvement. Gynecol Oncol. 2012 Oct; 127(1):43-6.
    View in: PubMed
    Score: 0.023
  13. Correlation of cone biopsy with findings at radical hysterectomy and use of adjuvant radiation therapy. Gynecol Oncol. 2012 Mar; 124(3):508-11.
    View in: PubMed
    Score: 0.022
  14. Isolated groin recurrence of vulvar cancer salvaged with multimodality therapy. Gynecol Oncol. 2009 Nov; 115(2):306-7.
    View in: PubMed
    Score: 0.019
  15. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):461-6.
    View in: PubMed
    Score: 0.018
  16. CA125 decline in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy. Gynecol Oncol. 2008 Nov; 111(2):233-6.
    View in: PubMed
    Score: 0.018
  17. Panniculectomy concurrent with anterior pelvic exenteration for recurrent cervical cancer. Gynecol Oncol. 2008 Feb; 108(2):449-51.
    View in: PubMed
    Score: 0.017
  18. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006 Nov; 103(2):667-72.
    View in: PubMed
    Score: 0.015
  19. Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor). BMC Cancer. 2025 Mar 18; 25(1):500.
    View in: PubMed
    Score: 0.014
  20. Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial. Gynecol Oncol. 2025 Apr; 195:122-133.
    View in: PubMed
    Score: 0.014
  21. Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Mar 13; 13(3).
    View in: PubMed
    Score: 0.014
  22. First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer. J Immunother Cancer. 2025 Jan 11; 13(1).
    View in: PubMed
    Score: 0.014
  23. Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892). Cancer Chemother Pharmacol. 2024 Dec 14; 95(1):4.
    View in: PubMed
    Score: 0.014
  24. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug; 34(8):1283-1289.
    View in: PubMed
    Score: 0.014
  25. ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
    View in: PubMed
    Score: 0.013
  26. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 06; 185:202-211.
    View in: PubMed
    Score: 0.013
  27. A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors. Clin Ther. 2024 Mar; 46(3):228-238.
    View in: PubMed
    Score: 0.013
  28. A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. Int J Gynecol Cancer. 2023 09 04; 33(9):1458-1463.
    View in: PubMed
    Score: 0.012
  29. Advances in antibody-drug conjugates for gynecologic malignancies. Curr Opin Obstet Gynecol. 2023 02 01; 35(1):6-14.
    View in: PubMed
    Score: 0.012
  30. Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev. 2023 03; 12(3):257-266.
    View in: PubMed
    Score: 0.012
  31. A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
    View in: PubMed
    Score: 0.011
  32. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 04; 161(1):113-121.
    View in: PubMed
    Score: 0.010
  33. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370.
    View in: PubMed
    Score: 0.010
  34. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion. Int J Gynecol Cancer. 2020 11; 30(11):1738-1747.
    View in: PubMed
    Score: 0.010
  35. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer. 2020 05; 30(5):596-601.
    View in: PubMed
    Score: 0.010
  36. Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy? Gynecol Oncol. 2020 03; 156(3):568-574.
    View in: PubMed
    Score: 0.010
  37. A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020 03 01; 106(3):464-471.
    View in: PubMed
    Score: 0.010
  38. Olaparib in the treatment of ovarian cancer. Future Oncol. 2019 Oct; 15(30):3435-3449.
    View in: PubMed
    Score: 0.009
  39. Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development. Curr Oncol Rep. 2019 02 26; 21(3):22.
    View in: PubMed
    Score: 0.009
  40. The Significance of Para-Aortic Nodal Size and the Role of Adjuvant Systemic Chemotherapy in Cervical Cancer: An Institutional Experience. Am J Clin Oncol. 2018 12; 41(12):1225-1230.
    View in: PubMed
    Score: 0.009
  41. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer. Am J Clin Oncol. 2018 10; 41(10):933-937.
    View in: PubMed
    Score: 0.009
  42. Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment. Am J Clin Oncol. 2018 05; 41(5):447-451.
    View in: PubMed
    Score: 0.009
  43. The prevalence of occult endometrial cancer in women undergoing hysterectomy for benign indications. Eur J Obstet Gynecol Reprod Biol. 2018 Apr; 223:108-112.
    View in: PubMed
    Score: 0.008
  44. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 09; 146(3):477-483.
    View in: PubMed
    Score: 0.008
  45. The opinions and practices of providers toward the sexual issues of cervical cancer patients undergoing treatment. Gynecol Oncol. 2017 03; 144(3):586-591.
    View in: PubMed
    Score: 0.008
  46. Factors influencing primary treatment of midline vulvar cancers. Gynecol Oncol. 2016 07; 142(1):133-138.
    View in: PubMed
    Score: 0.007
  47. Remote location interstitial brachytherapy with patient stabilization and subsequent transport to an outpatient center for treatment is safe and effective for the treatment of gynecologic malignancies. Brachytherapy. 2016 May-Jun; 15(3):341-346.
    View in: PubMed
    Score: 0.007
  48. Ovarian involvement in endometrioid adenocarcinoma of uterus. Gynecol Oncol. 2015 Sep; 138(3):532-5.
    View in: PubMed
    Score: 0.007
  49. Outcomes of Treatment of Gestational Trophoblastic Neoplasia in a Primarily Indigent Urban Population. J Reprod Med. 2015 May-Jun; 60(5-6):243-8.
    View in: PubMed
    Score: 0.007
  50. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015 Jan; 136(1):3-7.
    View in: PubMed
    Score: 0.007
  51. Adnexal masses requiring surgical intervention in women with advanced cervical cancer. Gynecol Oncol. 2014 Sep; 134(3):552-5.
    View in: PubMed
    Score: 0.007
  52. Factors associated with clinical trial screening failures in gynecologic oncology. Gynecol Oncol. 2014 Sep; 134(3):450-4.
    View in: PubMed
    Score: 0.007
  53. Malignant ovarian germ cell tumor - role of surgical staging and gonadal dysgenesis. Gynecol Oncol. 2014 Jul; 134(1):84-9.
    View in: PubMed
    Score: 0.007
  54. Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer? Int J Gynecol Cancer. 2013 Jun; 23(5):833-8.
    View in: PubMed
    Score: 0.006
  55. Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer. Clin Obstet Gynecol. 2012 Mar; 55(1):131-55.
    View in: PubMed
    Score: 0.006
  56. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecol Oncol. 2011 May 01; 121(2):269-72.
    View in: PubMed
    Score: 0.005
  57. Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy? Int J Gynecol Cancer. 2010 Oct; 20(7):1125-31.
    View in: PubMed
    Score: 0.005
  58. The prognostic significance of the triple negative phenotype in endometrial cancer. Gynecol Oncol. 2010 Aug 01; 118(2):172-5.
    View in: PubMed
    Score: 0.005
  59. Robotic pelvic and aortic lymphadenectomy for endometrial cancer: the console surgeon's perspectives on surgical technique and directing the assistant. J Minim Invasive Gynecol. 2010 Mar-Apr; 17(2):180-5.
    View in: PubMed
    Score: 0.005
  60. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer. Int J Gynecol Cancer. 2009 Oct; 19(7):1195-8.
    View in: PubMed
    Score: 0.005
  61. Metastatic squamous cell carcinoma of the vulva to the lung confirmed with allelotyping. Int J Gynecol Pathol. 2009 Sep; 28(5):497-501.
    View in: PubMed
    Score: 0.005
  62. A detailed analysis of the learning curve: robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Gynecol Oncol. 2009 Aug; 114(2):162-7.
    View in: PubMed
    Score: 0.005
  63. Paratubal borderline serous tumors. Gynecol Oncol. 2009 Apr; 113(1):83-5.
    View in: PubMed
    Score: 0.005
  64. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol. 2009 Jan; 113(1):11-17.
    View in: PubMed
    Score: 0.004
  65. Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer. Obstet Gynecol. 2008 Dec; 112(6):1207-1213.
    View in: PubMed
    Score: 0.004
  66. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol. 2009 Jan; 112(1):55-9.
    View in: PubMed
    Score: 0.004
  67. Local correction of extreme stomal prolapse following transverse loop colostomy. Gynecol Oncol. 2008 Dec; 111(3):549-51.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.